Bone marrow macrophage STING signaling is a direct nexus linking marrow adipose expansion to NAD⁺ depletion and osteogenic decline in skeletal aging

The intricate architecture of human and mammalian bones undergoes a lifelong, relentless cycle of renewal, balancing structural degradation and generation to maintain integrity. Osteoclasts dismantle old or damaged bone tissue, while osteoblasts synthesize new extracellular matrix to preserve skeletal strength. These osteoblasts originate from bone marrow mesenchymal stem cells (BMSCs), which maintain a dual developmental potential that also allows them to generate adipocytes, or fat cells. As organisms age, this delicate equilibrium shifts profoundly. Bone marrow progressively accumulates adipose tissue, adopting an increasingly pro-inflammatory state that inhibits effective bone formation. While this age-related skeletal degradation has long been recognized as a hallmark of senescence, the precise molecular drivers connecting marrow fat accumulation to declining bone synthesis have remained elusive until now.

A groundbreaking study published recently in the journal Advanced Science by a team of researchers in China sheds new light on this physiological deterioration. The investigation reveals that signals mediated by the cGAS-STING pathway within bone marrow immune cells act as a critical bridge between expanding marrow fat and the metabolic collapse of bone-forming cells. By identifying how age-related cellular stress triggers this inflammatory cascade, the research points toward promising therapeutic avenues capable of preserving skeletal structure in aging populations.

Unraveling the cGAS-STING Immune Signaling Cascade

To understand the mechanics of skeletal aging, the research team focused their attention on macrophages, specialized immune cells residing within the bone marrow microenvironment. Specifically, they investigated the cGAS-STING pathway, an ancient intracellular defense mechanism designed to detect misplaced double-stranded DNA floating freely in the cell’s cytoplasm. Under normal conditions, this pathway acts as a crucial frontline sentinel, identifying viral and bacterial pathogens by recognizing foreign genetic material.

However, as organisms age, this surveillance system frequently misfires. Accumulating cellular damage, particularly the leakage of mitochondrial DNA into the cytoplasm due to organelle stress, acts as an endogenous trigger. The enzyme cyclic GMP-AMP synthase (cGAS) detects this misplaced self-DNA and synthesizes the messenger molecule cGAMP. This secondary messenger subsequently binds to and activates stimulator of interferon genes (STING), initiating a robust downstream inflammatory response.

To track how this pathway changes over time, the researchers analyzed bone marrow samples from mice aged 3, 10, 18, and 24 months. The chronological data revealed a stark, progressive escalation in cGAS-STING activation alongside advancing age. Older subjects exhibited significantly higher concentrations of cytoplasmic DNA, elevated levels of cGAMP, and increased phosphorylation—a biochemical marker of activation—of STING and its downstream signaling partners. Furthermore, cell-population comparisons demonstrated that macrophages possessed the highest baseline expression of the Sting gene among marrow cell types, with their activation scaling directly with age. This established macrophages as a primary cellular locus for age-associated inflammatory signaling.

Experimental Interventions and Chronological Validation

Having identified macrophage STING as a correlate of skeletal aging, the investigative team sought to determine whether this pathway played a causative role in bone loss or merely served as a passive biomarker of degeneration. To test this hypothesis, the researchers employed a macrophage-specific viral vector to silence the Sting gene in mice transitioning from 12 to 18 months of age—a critical window during which age-related bone loss accelerates significantly in murine models.

The suppression of macrophage STING yielded profound physiological preservation. Treated mice exhibited significantly protected bone density and structural integrity compared to control cohorts. Quantitative analyses of the skeletal tissues confirmed an increase in markers associated with new bone deposition, alongside a notable reduction in the accumulation of marrow fat cells. These findings provided robust empirical evidence that macrophage STING activation is actively detrimental to bone homeostasis during aging.

To further dissect intercellular dynamics, the team evaluated the interaction between aged macrophages and young BMSCs in co-culture systems. While old macrophages typically impaired the capacity of young BMSCs to differentiate into osteoblasts, old macrophages genetically engineered to lack functional STING exhibited a markedly reduced capacity to inhibit BMSC development. This confirmed that macrophage-derived signals directly undermine the osteogenic potential of marrow stem cells.

The Multi-Pronged Trigger: Adipose Tissue Secretions and Mitochondrial Stress

Pursuing the upstream origins of macrophage STING activation, the researchers explored systemic and local environmental factors within the aging bone marrow. They observed that older mice harbored higher circulating and bone marrow concentrations of endotoxins, such as bacterial lipopolysaccharide (LPS), which are known to stimulate innate immune pathways. However, the study uncovered an even more localized driver: secretions from aging marrow adipose tissue.

When young mouse bone marrow was exposed to conditioned media derived from old marrow fat cells, or when old fat cell secretions were directly injected into the marrow of young subjects, macrophage STING activation was rapidly induced. To pinpoint the specific molecular mediators responsible for this phenomenon, the team screened 44 distinct proteins found to be upregulated in aging bone marrow. Among these, soluble dipeptidyl peptidase-4 (DPP4) emerged as a standout candidate. Fat cells released substantially higher quantities of DPP4 than any other tested marrow cell population, with old adipocytes secreting significantly elevated levels compared to young counterparts.

Administering DPP4 directly into the bone marrow of young mice over a four-week period successfully replicated the detrimental phenotype, worsening bone density and architecture while activating macrophage STING. Biochemical assays revealed that DPP4 acts cooperatively within the inflammatory milieu, binding to the cell-surface receptor TLR4 (Toll-like receptor 4) on macrophages to amplify STING signaling rather than acting as a solitary trigger.

Concurrently, the researchers observed severe mitochondrial distress within aging macrophages, characterized by an abnormal accumulation of mitochondrial DNA outside the organelles. Utilizing low-dose ethidium bromide to reduce cytoplasmic mitochondrial DNA partially abrogated STING activation. This led the authors to conclude that external inflammatory signals, mediated by the DPP4-TLR4 axis, act in synergy with internal mitochondrial damage to maintain chronic STING activity in aging bone marrow.

Metabolic Fallout: The NAD⁺ and CD38 Connection

Beyond direct inflammatory suppression of osteogenesis, the research uncovered a critical metabolic consequence tied to chronic STING activation: the depletion of nicotinamide adenine dinucleotide (NAD⁺), an essential coenzyme required for cellular energy metabolism, mitochondrial function, and longevity pathways.

Measurements of macrophage NAD⁺ pools revealed a steep age-related decline, driven by an upregulation of NAD⁺-degrading enzymatic activity. The data indicated that sustained STING signaling stimulates the expression of CD38, a major NAD⁺-consuming ectoenzyme located on the cell surface. This surface-bound CD38 degrades extracellular NAD⁺ and its key precursor, nicotinamide mononucleotide (NMN), effectively starving neighboring cells of the vital metabolite.

As a result, young BMSCs exposed to the conditioned environment of activated old macrophages exhibited severe mitochondrial dysfunction and diminished production of adenosine triphosphate (ATP), the primary cellular energy currency. Supplementing the culture media with NMN partially rescued these metabolic metrics, though rescue efficiency was constrained in the presence of hyperactive old macrophages. Conversely, genetic knockout of Sting or Cd38 in macrophages restored normal mitochondrial respiration in co-cultured stem cells.

Implications of Pharmacological Combinations and Future Therapeutic Horizons

To translate these mechanistic insights into a viable therapeutic strategy, the researchers tested a combined pharmacological intervention in mice aged 12 to 18 months. The animals received a regimen pairing H-151, a selective small-molecule inhibitor of STING, with dietary or systemic NMN supplementation.

The dual therapy yielded comprehensive systemic and structural benefits. Treated mice maintained robust bone density and trabecular architecture, demonstrated elevated rates of new bone formation, exhibited suppressed markers of localized inflammation, and restored physiological NAD⁺ levels and mitochondrial function within BMSCs. Notably, the therapeutic efficacy of the H-151 and NMN combination matched the performance of alendronate, a widely prescribed clinical bisphosphonate used as a positive control in the study.

Independent biomedical analysts and bone biology specialists have noted that these findings mark a significant conceptual shift in osteoporosis research. Rather than focusing solely on inhibiting bone resorption—the traditional mechanism of action for most anti-osteoporosis drugs—this approach targets the root inflammatory and metabolic drivers of skeletal aging within the bone marrow microenvironment. By addressing the crosstalk between expanding marrow adipose tissue, innate immune activation, and systemic NAD⁺ depletion, combinatorial therapies may eventually offer a way to regenerate lost skeletal mass rather than merely halting its destruction.

Despite these promising findings, researchers involved in the study emphasize several important limitations that must be addressed in subsequent investigations. The murine experiments relied on relatively small cohort sizes, and the combinatorial nature of the final intervention trial—pairing a STING inhibitor with an NAD⁺ precursor—makes it difficult to definitively isolate the individual contributions of each therapeutic agent. Furthermore, translating these murine pathways to human clinical populations will require extensive validation, given species-specific differences in immune cell distribution and bone turnover rates.

As aging populations expand globally, age-related bone diseases such as osteoporosis represent an escalating public health and economic burden, frequently resulting in debilitating fractures, loss of independence, and increased mortality. By mapping the precise molecular signaling cascades that connect marrow fat accumulation to osteogenic failure, this study opens new pathways for anti-aging medicine. Future clinical trials focusing on targeted immunomodulatory agents and metabolic replenishment strategies may ultimately provide older adults with robust defenses against the silent degeneration of their skeletal framework.